Internal Medicine, Endocrinology, Diabetes, & Metabolism · St Petersburg, FL
NPI
1104982420
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
5775 5th Ave N
St Petersburg, FL, 33710
Phone (727) 345-5222
Groups this clinician bills Medicare through
Medicare paid, 2024
$275K
3,642 services
Medicare patients, 2024
683
Average age 74
Drug cost, 2024
$5.1M
11,293 prescriptions
Company payments, 2025
$54K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ajay Varanasi was code 99214 (office e&m - established), 1,826 times for 645 patients. In total Ajay Varanasi billed 3,642 services in 17 codes, and Medicare paid $275K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,826 | 645 | $92.48 | $169K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 810 | 165 | $50.07 | $41K |
| 95251 Test - Miscellaneous | Office | 389 | 156 | $25.82 | $10K |
| 76536 Ultrasound - Nonspecific | Office | 169 | 156 | $76.24 | $13K |
| 99213 Office E&M - Established | Office | 123 | 108 | $68.09 | $8,375 |
| 99215 Office E&M - Established | Office | 106 | 81 | $123.71 | $13K |
| 99204 Office E&M - New | Office | 104 | 104 | $121.55 | $13K |
| 95250 Test - Miscellaneous | Office | 29 | 29 | $106.00 | $3,074 |
| 10005 Other Organ Systems | Office | 27 | 25 | $108.17 | $2,921 |
| 99212 Office E&M - Established | Office | 25 | 25 | $41.47 | $1,037 |
| 93922 Duplex Scan - Extremity Arteries | Office | 18 | 18 | $61.12 | $1,100 |
By year: 2022 $291K for 5,952 services; 2023 $262K for 3,878 services; 2024 $275K for 3,642 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ajay Varanasi prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,511 prescriptions and refills. In total Ajay Varanasi wrote 11,293 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,511 | 3,986 | 436 | $16K |
| Ozempic Semaglutide | 729 | 1,245 | 179 | $1.1M |
| Metformin Hcl Generic | 571 | 1,587 | 196 | $3,170 |
| Mounjaro Tirzepatide | 434 | 676 | 102 | $709K |
| Atorvastatin Calcium Generic | 431 | 1,119 | 145 | $4,723 |
| Jardiance Empagliflozin | 362 | 823 | 102 | $466K |
| Trulicity Dulaglutide | 351 | 586 | 94 | $573K |
| Rosuvastatin Calcium Generic | 301 | 823 | 109 | $3,447 |
| Synthroid Levothyroxine Sodium | 279 | 705 | 81 | $28K |
| Glimepiride Generic | 257 | 715 | 91 | $2,679 |
| Tresiba Flextouch U-200 Insulin Degludec | 255 | 556 | 68 | $280K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 253 | 561 | 85 | $47K |
| Losartan Potassium Generic | 233 | 612 | 77 | $2,733 |
| Lisinopril Generic | 221 | 562 | 74 | $1,129 |
| Methimazole Generic | 214 | 574 | 70 | $1,829 |
Brand drugs: 5,486 claims; generic drugs: 5,011 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ajay Varanasi $54K ($54K in general payments such as food, travel and fees) from 18 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $45K.
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc ASND | 37 | $45K |
| Dexcom, Inc. DXCM | 6 | $8,293 |
| Abbott Laboratories ABT | 4 | $255 |
| Novo Nordisk Inc NVO | 15 | $222 |
| Lilly USA, LLC LLY | 12 | $173 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $112 |
| RGH Enterprises LLC | 1 | $63 |
| Globus Medical, Inc. GMED | 2 | $43.23 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $41.92 |
| Tandem Diabetes Care, Inc. TNDM | 3 | $41.57 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.